Fisher & Paykel Healthcare Co Ltd 2021 AR2
The report highlights Fisher & Paykel Healthcare's performance and sustainability initiatives for the fiscal year ended March 31, 2021. Amidst the global pandemic, the company scaled up production of its Optiflow nasal high flow therapy devices to meet surging demand, treating approximately 20 million patients. Financially, operating revenue increased by 56% to $1.97 billion, and net profit after tax rose by 82% to $524.2 million. On the sustainability front, the company committed $20 million to establish the Fisher & Paykel Healthcare Foundation and set science-based targets to reduce Scope 1 and 2 emissions by 4.2% annually.
Company: Fisher & Paykel Healthcare Co Ltd
Sector: Manufacturing
Country: New Zealand
Year: 2021
Type: AR2
Pages: 148
Fisher & Paykel Healthcare Co Ltd
The report highlights Fisher & Paykel Healthcare's performance and sustainability initiatives for the fiscal year ended March 31, 2021. Amidst the global pandemic, the company scaled up production of its Optiflow nasal high flow therapy devices to meet surging demand, treating approximately 20 million patients. Financially, operating revenue increased by 56% to $1.97 billion, and net profit after tax rose by 82% to $524.2 million. On the sustainability front, the company committed $20 million to establish the Fisher & Paykel Healthcare Foundation and set science-based targets to reduce Scope 1 and 2 emissions by 4.2% annually.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Apr 1, 2020 - Mar 31, 2021
Fiscal Year
2021
Published
May 26, 2021
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Water Consumption
Women on Board
Women in Management
Workplace Fatalities
Employees